Glimepiride, the first of a new generation of sulfonylurea drugs, was introduced in
Sweden in 1995 as a first-line therapy to lower blood glucose in patients with type II
diabetes. Sulfonylureas exert their hypoglycemic function primarily by direct
stimulation of insulin secretion in glucose-insensitive pancreatic β-cells and GLUT
translocation in insulin-resistant fat and muscle cells. Once-daily, orally administered
glimepiride in diabetes patients showed a more rapid and longer lasting glucose-lowering
effect than the commonly used agent glibenclamide. Glimepiride can be used either as
a monotherapy or in combination with insulin.
화학적 성질
White Cyrstalline Solid
용도
Glimepiride induces the PI3 kinase (PI3K) and Akt pathway, along with insulin receptor substrate-1/2 and endothelial nitric oxide synthase. Glimepiride also increases osteoblast proliferation and differentiation, which is thought to be related to its ability to activate the PI3K and Akt pathway. Furthermore, Glimepiride enhances intrinsic peroxisome proliferator-activated receptor γ activity. Glimepiride also increases protein expression of glucose transports 1 and 4, and is a potent KIR channel blocker. Potent Kir6 (KATP) channel blocker and anti-diabetic agent. Inhibits pinacidil-activated cardiac Kir6 channels with an IC50 of 6.8 nM.
일반 설명
Glimepiride is 3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(trans-4-methylcyclohexyl)amino]-carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide; thiscompound can also be named as the urea—see precedingdiscussion (Amaryl, generic). Combinations are availablewith rosiglitazone in the United States (Avandaryl tablets;mg glimepiride/mg rosiglitazone as maleate salt: 1/4,2/4, 4/4, 2/8, 4/8); and with pioglitazone (Duetact tablets;mg glimepiride/ mg pioglitazone as hydrochloride salt:2/30, 4/30).
생물학적 활성
Potent K ATP channel blocker and anti-diabetic agent. Inhibits pinacidil-activated cardiac K ATP channels with an IC 50 of 6.8 nM.
